David Wilson

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Cooley advised Uber Technologies on its $5 billion investment-grade revolving credit facility.

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.

Cooley advised ChrysCapital, a top India-focused private equity firm, on the close of its oversubscribed $700 million continuation fund and general partner-led secondary transaction to purchase and sell its stake in the National Stock Exchange of India (NSE) with two of the world’s leading secondary fund investors. The landmark transaction is the largest of its kind in India and ranks among the largest in the Asia-Pacific region.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.